Home Cart Sign in  
Chemical Structure| 34170-21-3 Chemical Structure| 34170-21-3

Structure of 34170-21-3

Chemical Structure| 34170-21-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 34170-21-3 ]

CAS No. :34170-21-3
Formula : C9H12N2OS
M.W : 196.27
SMILES Code : O=C1NC(SC)=NC2=C1CCCC2
MDL No. :MFCD08744204
InChI Key :UCIOWMDHSRPCFY-UHFFFAOYSA-N
Pubchem ID :135435256

Safety of [ 34170-21-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 34170-21-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.56
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 54.01
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

71.05 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.94
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.43
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.37
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.38
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.95
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.81

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.23
Solubility 1.15 mg/ml ; 0.00584 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.53
Solubility 0.583 mg/ml ; 0.00297 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.17
Solubility 0.132 mg/ml ; 0.000675 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.48 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.36

Application In Synthesis of [ 34170-21-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 34170-21-3 ]

[ 34170-21-3 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 34170-21-3 ]
  • [ 51660-11-8 ]
YieldReaction ConditionsOperation in experiment
43% at 110℃; To a mixture of ethyl 2-cyclohexanonecarboxylate (3.00 g, 17.6 mmol) and 2-methyl-2- thiopseudourea sulfate (3.68 g, 13.2 mmol) was added a solution of potassium carbonate (7.31 g, 52.9 mmol) in water (60 mL). The reaction solution was stirred at room temperature for 16 h, at which time it was observed to be a suspension. The white solid was collected by vacuum filtration, washed with water, and dried in vacuo. A mixture of the solid in phosphorus oxychloride (20 mL) was heated at [110°C] in a sealed tube, at which time it was observed to be a solution. The solution was cooled to room temperature and was then poured over cracked ice and water (300 [ML).] The mixture was vigorously stirred at 0°C for 1 h, and the resulting precipitate was collected by vacuum filtration, washed with water, and dried in vacuo to afford 1.61 g of 2-thiomethyl-4-chloro-5, 6,7, 8-tetrahydroquinazoline (43percent) as an off-white solid. To a solution [OF 2-THIOMETHYL-4-CHLORO-5,] 6,7, 8-tetrahydroquinazoline (0.5121 g, 2.39 mmol) in a 10: [1] mixture of MeOH-HOAc (30 mL) was added activated zinc dust (500 mg, 7.65 mmol). The mixture was heated at [70°C] for 1 h, and was then cooled to room temperature and filtered. The resulting solution was concentrated in vacuo, and azeotropically dried with toluene (50 mL). The residue was partitioned between EtOAc (150 mL) and 1 N aq. [HC1] (50 mL), and the organic phase was then washed with saturated aq. [NAHCO3] and brine. The organic phase was then dried over anhydrous [MGSO4] and concentrated in vacuo to provide 0.1461 g of 2- thiomethyl-5,6, 7,8-tetrahydroquinazoline (34percent) as a purple oil. To a solution of 2-thiomethyl-5, 6,7, 8-tetrahydroquinazoline (0.1461 g, 0.81 mmol) in [CH2CL2] (5 mL) was added m-chloroperbenzoic acid (0.462 g, 2.68 [MMOL).] The solution was stirred at room temperature for 3 h at which time it was observed to be a suspension. The solvent was then removed in vacuo, and [MEOH] (5 [ML)] was added followed by hydrazine monohydrate (1 mL, 20.6 mmol). The solution was then heated at [50°C] and stirred for 16 h. The solution was cooled to room temperature and purified by reverse phase HPLC to give 0.1126 g of the title compound [(85percent)] as a colorless oil. MH+ 165.
References: [1] Patent: WO2003/101442, 2003, A1, . Location in patent: Page 55.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 34170-21-3 ]

Amides

Chemical Structure| 20651-30-3

A488420 [20651-30-3]

5-Methyl-2-(methylthio)pyrimidin-4(3H)-one

Similarity: 0.75

Chemical Structure| 89487-99-0

A387304 [89487-99-0]

4-Hydroxy-2-(methylthio)pyrimidine-5-carbonitrile

Similarity: 0.70

Chemical Structure| 109229-22-3

A141344 [109229-22-3]

6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one

Similarity: 0.65

Chemical Structure| 19181-54-5

A247355 [19181-54-5]

8-Methylquinazolin-4(3H)-one

Similarity: 0.65

Chemical Structure| 5751-20-2

A129850 [5751-20-2]

2-(Methylthio)pyrimidin-4(3H)-one

Similarity: 0.64

Sulfides

Chemical Structure| 20651-30-3

A488420 [20651-30-3]

5-Methyl-2-(methylthio)pyrimidin-4(3H)-one

Similarity: 0.75

Chemical Structure| 89487-99-0

A387304 [89487-99-0]

4-Hydroxy-2-(methylthio)pyrimidine-5-carbonitrile

Similarity: 0.70

Chemical Structure| 5751-20-2

A129850 [5751-20-2]

2-(Methylthio)pyrimidin-4(3H)-one

Similarity: 0.64

Chemical Structure| 53554-29-3

A136541 [53554-29-3]

Ethyl 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxylate

Similarity: 0.62

Chemical Structure| 902576-09-4

A310645 [902576-09-4]

2-(Methylthio)pyrido[4,3-d]pyrimidin-5(6H)-one

Similarity: 0.59

Related Parent Nucleus of
[ 34170-21-3 ]

Other Aromatic Heterocycles

Chemical Structure| 109229-22-3

A141344 [109229-22-3]

6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one

Similarity: 0.65

Chemical Structure| 62458-96-2

A414868 [62458-96-2]

7-Benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one

Similarity: 0.63

Chemical Structure| 93076-03-0

A103258 [93076-03-0]

3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride

Similarity: 0.60

Chemical Structure| 63234-80-0

A123984 [63234-80-0]

3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Similarity: 0.60

Chemical Structure| 26493-11-8

A754416 [26493-11-8]

2-Amino-6,7-dihydrothiazolo[5,4-c]pyridin-4(5H)-one

Similarity: 0.60